Repository logo
 

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population.

Simple item page
cam.issuedOnline2022-04-24
dc.contributor.authorBarr, Chloe E
dc.contributor.authorFunston, Garth
dc.contributor.authorJeevan, David
dc.contributor.authorSundar, Sudha
dc.contributor.authorMounce, Luke TA
dc.contributor.authorCrosbie, Emma J
dc.contributor.orcidFunston, Garth [0000-0002-4156-6401]
dc.contributor.orcidCrosbie, Emma J [0000-0003-0284-8630]
dc.date.accessioned2022-06-15T01:05:14Z
dc.date.available2022-06-15T01:05:14Z
dc.date.issued2022-04-24
dc.date.updated2022-06-15T01:05:14Z
dc.description.abstractHuman epididymis 4 (HE4) is a promising ovarian cancer biomarker, but it has not been evaluated in primary care. In this prospective observational study, we investigated the diagnostic accuracy of HE4 alone and in combination with CA125 for the detection of ovarian cancer in symptomatic women attending primary care. General practitioner (GP)-requested CA125 samples were tested for HE4 at a large teaching hospital in Manchester, and cancer outcomes were tracked for 12 months. We found a low incidence of ovarian cancer in primary care; thus, the cohort was enriched with pre-surgical samples from 81 ovarian cancer patients. The Risk of Ovarian Malignancy Algorithm (ROMA) was calculated using age (</>51) as a surrogate for menopause. Conventional diagnostic accuracy metrics were determined. A total of 1229 patients were included; 82 had ovarian cancer. Overall, ROMA performed best (AUC-0.96 (95%CI: 0.94−0.98, p = <0.001)). In women under 50 years, the combination of CA125 and HE4 (either marker positive) was superior (sensitivity: 100% (95%CI: 81.5−100.0), specificity: 80.1% (95%CI 76.7−83.1)). In women over 50, ROMA performed best (sensitivity: 84.4% (95%CI: 73.1−92.2), specificity: 87.2% (95%CI 84.1−90)). HE4 and ROMA may improve ovarian cancer detection in primary care, particularly for women under 50 years, in whom diagnosis is challenging. Validation in a larger primary care cohort is required.
dc.description.sponsorshipLumipulse®G HE4 immunoassay kits were generously donated by Fujirebio for use in this re-search. Fujirebio played no other role in the conduct of this study, analysis of the data or the deci-sion to publish. CEB was supported through an MFT Clinical Research Fellowship and EJC through the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). This work was supported by Wellbeing of Women (Award Reference ELS701) (GF, EJC). DJ was supported by Wellbeing of Women (Award Reference RTF707).
dc.identifier.doi10.17863/CAM.85514
dc.identifier.eissn2072-6694
dc.identifier.issn2072-6694
dc.identifier.other35565253
dc.identifier.otherPMC9101616
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338105
dc.languageeng
dc.language.isoeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101526829
dc.sourceessn: 2072-6694
dc.subjectCA125
dc.subjectHE4
dc.subjectROMA
dc.subjectbiomarker
dc.subjectearly detection
dc.subjectovarian cancer
dc.subjectprimary care
dc.titleThe Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population.
dc.typeArticle
dcterms.dateAccepted2022-04-19
prism.issueIdentifier9
prism.publicationNameCancers (Basel)
prism.volume14
pubs.funder-project-idWellbeing of Women (RTF707, ELS701)
pubs.funder-project-idNational Institute for Health Research (NIHR) (IS-BRC-1215-20007, NIHR300650)
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cancers14092124

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
article.pdf
Size:
2.09 MB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by/4.0/
Download

Collections

Jisc Publications Router